Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus

Hiroaki Uchida, Marco Marzulli, kenji nakano, William F. Goins, Janet Chan, Chang Sook Hong, Lucia Mazzacurati, Ji Young Yoo, Amy Haseley, Hiroshi Nakashima, Hyunjung Baek, Heechung Kwon, Izumi Kumagai, Masahide Kuroki, Balveen Kaur, E. Antonio Chiocca, Paola Grandi, Justus B. Cohen, Joseph C. Glorioso

    Research output: Contribution to journalArticle

    42 Citations (Scopus)

    Abstract

    Glioblastoma multiforme (GBM) remains an untreatable human brain malignancy. Despite promising preclinical studies using oncolytic herpes simplex virus (oHSV) vectors, efficacy in patients has been limited by inefficient virus replication in tumor cells. This disappointing outcome can be attributed in part to attenuating mutations engineered into these viruses to prevent replication in normal cells. Alternatively, retargeting of fully replication-competent HSV to tumor-associated receptors has the potential to achieve tumor specificity without impairment of oncolytic activity. Here, we report the establishment of an HSV retargeting system that relies on the combination of two engineered viral glycoproteins, gD and gB, to mediate highly efficient HSV infection exclusively through recognition of the abundantly expressed epidermal growth factor receptor (EGFR) on glioblastoma cells. We demonstrate efficacy in vitro and in a heterotopic tumor model in mice. Evidence for systemically administered virus homing to the tumor mass is presented. Treatment of orthotopic primary human GBM xenografts demonstrated prolonged survival with up to 73% of animals showing a complete response as confirmed by magnetic resonance imaging. Our study describes an approach to HSV retargeting that is effective in a glioma model and may be applicable to the treatment of a broad range of tumor types.

    Original languageEnglish
    Pages (from-to)561-569
    Number of pages9
    JournalMolecular Therapy
    Volume21
    Issue number3
    DOIs
    Publication statusPublished - Jan 1 2013

    Fingerprint

    Oncolytic Viruses
    Simplexvirus
    Glioblastoma
    Epidermal Growth Factor Receptor
    Heterografts
    Neoplasms
    Therapeutics
    Viruses
    Virus Replication
    Glioma
    Glycoproteins
    Magnetic Resonance Imaging
    Mutation
    Survival
    Brain
    Infection

    All Science Journal Classification (ASJC) codes

    • Molecular Medicine
    • Molecular Biology
    • Genetics
    • Pharmacology
    • Drug Discovery

    Cite this

    Uchida, H., Marzulli, M., nakano, K., Goins, W. F., Chan, J., Hong, C. S., ... Glorioso, J. C. (2013). Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus. Molecular Therapy, 21(3), 561-569. https://doi.org/10.1038/mt.2012.211

    Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus. / Uchida, Hiroaki; Marzulli, Marco; nakano, kenji; Goins, William F.; Chan, Janet; Hong, Chang Sook; Mazzacurati, Lucia; Yoo, Ji Young; Haseley, Amy; Nakashima, Hiroshi; Baek, Hyunjung; Kwon, Heechung; Kumagai, Izumi; Kuroki, Masahide; Kaur, Balveen; Chiocca, E. Antonio; Grandi, Paola; Cohen, Justus B.; Glorioso, Joseph C.

    In: Molecular Therapy, Vol. 21, No. 3, 01.01.2013, p. 561-569.

    Research output: Contribution to journalArticle

    Uchida, H, Marzulli, M, nakano, K, Goins, WF, Chan, J, Hong, CS, Mazzacurati, L, Yoo, JY, Haseley, A, Nakashima, H, Baek, H, Kwon, H, Kumagai, I, Kuroki, M, Kaur, B, Chiocca, EA, Grandi, P, Cohen, JB & Glorioso, JC 2013, 'Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus', Molecular Therapy, vol. 21, no. 3, pp. 561-569. https://doi.org/10.1038/mt.2012.211
    Uchida, Hiroaki ; Marzulli, Marco ; nakano, kenji ; Goins, William F. ; Chan, Janet ; Hong, Chang Sook ; Mazzacurati, Lucia ; Yoo, Ji Young ; Haseley, Amy ; Nakashima, Hiroshi ; Baek, Hyunjung ; Kwon, Heechung ; Kumagai, Izumi ; Kuroki, Masahide ; Kaur, Balveen ; Chiocca, E. Antonio ; Grandi, Paola ; Cohen, Justus B. ; Glorioso, Joseph C. / Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus. In: Molecular Therapy. 2013 ; Vol. 21, No. 3. pp. 561-569.
    @article{917472d648b5484db95c5ae432f7cb25,
    title = "Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus",
    abstract = "Glioblastoma multiforme (GBM) remains an untreatable human brain malignancy. Despite promising preclinical studies using oncolytic herpes simplex virus (oHSV) vectors, efficacy in patients has been limited by inefficient virus replication in tumor cells. This disappointing outcome can be attributed in part to attenuating mutations engineered into these viruses to prevent replication in normal cells. Alternatively, retargeting of fully replication-competent HSV to tumor-associated receptors has the potential to achieve tumor specificity without impairment of oncolytic activity. Here, we report the establishment of an HSV retargeting system that relies on the combination of two engineered viral glycoproteins, gD and gB, to mediate highly efficient HSV infection exclusively through recognition of the abundantly expressed epidermal growth factor receptor (EGFR) on glioblastoma cells. We demonstrate efficacy in vitro and in a heterotopic tumor model in mice. Evidence for systemically administered virus homing to the tumor mass is presented. Treatment of orthotopic primary human GBM xenografts demonstrated prolonged survival with up to 73{\%} of animals showing a complete response as confirmed by magnetic resonance imaging. Our study describes an approach to HSV retargeting that is effective in a glioma model and may be applicable to the treatment of a broad range of tumor types.",
    author = "Hiroaki Uchida and Marco Marzulli and kenji nakano and Goins, {William F.} and Janet Chan and Hong, {Chang Sook} and Lucia Mazzacurati and Yoo, {Ji Young} and Amy Haseley and Hiroshi Nakashima and Hyunjung Baek and Heechung Kwon and Izumi Kumagai and Masahide Kuroki and Balveen Kaur and Chiocca, {E. Antonio} and Paola Grandi and Cohen, {Justus B.} and Glorioso, {Joseph C.}",
    year = "2013",
    month = "1",
    day = "1",
    doi = "10.1038/mt.2012.211",
    language = "English",
    volume = "21",
    pages = "561--569",
    journal = "Molecular Therapy",
    issn = "1525-0016",
    publisher = "Nature Publishing Group",
    number = "3",

    }

    TY - JOUR

    T1 - Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus

    AU - Uchida, Hiroaki

    AU - Marzulli, Marco

    AU - nakano, kenji

    AU - Goins, William F.

    AU - Chan, Janet

    AU - Hong, Chang Sook

    AU - Mazzacurati, Lucia

    AU - Yoo, Ji Young

    AU - Haseley, Amy

    AU - Nakashima, Hiroshi

    AU - Baek, Hyunjung

    AU - Kwon, Heechung

    AU - Kumagai, Izumi

    AU - Kuroki, Masahide

    AU - Kaur, Balveen

    AU - Chiocca, E. Antonio

    AU - Grandi, Paola

    AU - Cohen, Justus B.

    AU - Glorioso, Joseph C.

    PY - 2013/1/1

    Y1 - 2013/1/1

    N2 - Glioblastoma multiforme (GBM) remains an untreatable human brain malignancy. Despite promising preclinical studies using oncolytic herpes simplex virus (oHSV) vectors, efficacy in patients has been limited by inefficient virus replication in tumor cells. This disappointing outcome can be attributed in part to attenuating mutations engineered into these viruses to prevent replication in normal cells. Alternatively, retargeting of fully replication-competent HSV to tumor-associated receptors has the potential to achieve tumor specificity without impairment of oncolytic activity. Here, we report the establishment of an HSV retargeting system that relies on the combination of two engineered viral glycoproteins, gD and gB, to mediate highly efficient HSV infection exclusively through recognition of the abundantly expressed epidermal growth factor receptor (EGFR) on glioblastoma cells. We demonstrate efficacy in vitro and in a heterotopic tumor model in mice. Evidence for systemically administered virus homing to the tumor mass is presented. Treatment of orthotopic primary human GBM xenografts demonstrated prolonged survival with up to 73% of animals showing a complete response as confirmed by magnetic resonance imaging. Our study describes an approach to HSV retargeting that is effective in a glioma model and may be applicable to the treatment of a broad range of tumor types.

    AB - Glioblastoma multiforme (GBM) remains an untreatable human brain malignancy. Despite promising preclinical studies using oncolytic herpes simplex virus (oHSV) vectors, efficacy in patients has been limited by inefficient virus replication in tumor cells. This disappointing outcome can be attributed in part to attenuating mutations engineered into these viruses to prevent replication in normal cells. Alternatively, retargeting of fully replication-competent HSV to tumor-associated receptors has the potential to achieve tumor specificity without impairment of oncolytic activity. Here, we report the establishment of an HSV retargeting system that relies on the combination of two engineered viral glycoproteins, gD and gB, to mediate highly efficient HSV infection exclusively through recognition of the abundantly expressed epidermal growth factor receptor (EGFR) on glioblastoma cells. We demonstrate efficacy in vitro and in a heterotopic tumor model in mice. Evidence for systemically administered virus homing to the tumor mass is presented. Treatment of orthotopic primary human GBM xenografts demonstrated prolonged survival with up to 73% of animals showing a complete response as confirmed by magnetic resonance imaging. Our study describes an approach to HSV retargeting that is effective in a glioma model and may be applicable to the treatment of a broad range of tumor types.

    UR - http://www.scopus.com/inward/record.url?scp=84875215479&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84875215479&partnerID=8YFLogxK

    U2 - 10.1038/mt.2012.211

    DO - 10.1038/mt.2012.211

    M3 - Article

    C2 - 23070115

    AN - SCOPUS:84875215479

    VL - 21

    SP - 561

    EP - 569

    JO - Molecular Therapy

    JF - Molecular Therapy

    SN - 1525-0016

    IS - 3

    ER -